|
Patent landscape, scope, and claims: |
Scope and Claims Analysis for US Patent 12,410,195 (United States Drug Patent): What’s Covered, Claim Breadth, and the US Patent Landscape
US Patent 12,410,195 is directed to a pharmaceutical composition that contains two chemical entities: a Formula I compound and a Formula II compound, each provided as a free base or pharmaceutically acceptable salt, with protection extending to specific weight-ratio windows, tablet/capsule dosage forms, and specific excipient sets in the formulation. The claims are structured to capture broad composition protection (Formula I + Formula II together) while adding layers of narrower control using (i) weight ratios and (ii) formulation/excipient selections including toluene sulfonic acid (tosylate) for Formula II, plus common tablet excipient functional classes.
What does US Patent 12,410,195 claim cover: the core composition and its legal scope?
Short answer: The independent claim covers a pharmaceutical composition that includes both (a) a Formula I compound and (b) a Formula II compound, each in free base or pharmaceutically acceptable salt form. All other limitations in dependent claims narrow by ratio, dosage form, specific salt selection for Formula II (tosylate), and excipient selections.
Claim 1 (independent): two-compound combination composition
Claim 1 requires, in one composition:
- A pharmaceutical composition comprising
- (i) a compound of Formula I in free base or pharmaceutically acceptable salt form; and
- (ii) a compound of Formula II in free base or pharmaceutically acceptable salt form.
Legal scope impact
- Claim 1 is a combination-of-compounds claim: infringement is triggered by the presence of both Formula I and Formula II in the same pharmaceutical composition.
- “Pharmaceutically acceptable salt form” broadens coverage because it is not limited to a single salt unless a dependent claim further narrows it (see claim 8).
Design-around angle
- A generic or alternative development team can only avoid Claim 1 by eliminating one required component: either not including Formula I, or not including Formula II, or using a form that is argued not to be within “pharmaceutically acceptable salts.” The latter is fact-intensive and typically not a clean workaround.
Claims 2-6: weight ratio windows that tighten the combination
Claim 2 adds a required weight ratio (Formula I : Formula II) from 1:200 to 1:2000.
Claims 3-6 then define narrower ratio bands:
- Claim 3: 1:245 to 1:1000
- Claim 4: 1:250 to 1:550
- Claim 5: 1:300 to 1:500
- Claim 6: 1:285 to 1:460
Legal scope impact
- These dependent claims create a layered infringement map: if a product falls inside a narrower band, it can still infringe even if the broader band is avoided. In practice, the narrow bands are subsets of broader ones (e.g., 1:300 to 1:500 sits inside 1:245 to 1:1000 and inside 1:200 to 1:2000).
- If an accused product’s ratio is outside Claim 2’s 1:200 to 1:2000, it may avoid Claim 2 and also all ratio-dependent claims that depend on Claim 2. That becomes a key formulation parameter for clearance.
Claim 7: dosage form limitation
- Claim 7: pharmaceutical composition is a tablet or capsule.
Legal scope impact
- Claim 7 narrows the composition scope to oral solid formats. If a candidate product uses another dosage form (e.g., solution, suspension, film-coated strip as a strip technology argument, implant, etc.), it may avoid the tablet/capsule limitation for these dependent claims. Claim 1 itself is not explicitly limited to tablet/capsule, but dependent coverage still matters in litigation because accused products are usually analyzed against all asserted claims.
Claim 8: Formula II specific salt
- Claim 8: compound of Formula II is in toluene sulfonic acid addition salt form.
Legal scope impact
- This is a targeted narrowing: it captures formulations where Formula II uses a particular salt (tosylate).
- Products using Formula II in other pharmaceutically acceptable salts (e.g., HCl, maleate, fumarate) may avoid Claim 8 while remaining exposed to Claim 1 and other claims.
Claims 9-24: excipient class selection and specific multi-excipient compositions
Claim 9 adds “further comprises at least one pharmaceutically acceptable diluent or carrier” in admixture with both actives.
Claim 10 lists excipient functional categories (a)-(u), including:
- antioxidant, binder, buffer, colorant, desiccant, diluent, disintegrant, drying agent, dye, effervescent, filler, flavor, glidant, humectant, lubricant, plasticizer, polymer, surfactant, sweetener, thickening agent, wetting agent.
Claim 11 narrows Claim 10 excipient options to:
- anti-oxidant; binder; diluent; disintegrant; filler; glidant; lubricant; sweetener; thickening agent.
Then claims 12-19 specify example members within these groups:
- Claim 12 (antioxidant): ascorbic acid, BHT, citric acid, propyl gallate, sodium metabisulfite.
- Claim 13 (binder): copovidone, hydroxypropyl cellulose, hydroxypropyl methyl cellulose.
- Claim 14 (diluent/filler): cellulose, dicalcium phosphate, isomalt, lactose monohydrate, mannitol.
- Claim 15: microcrystalline cellulose.
- Claim 16: silicified microcrystalline cellulose.
- Claim 17 (disintegrant): croscarmellose sodium, crospovidone, sodium starch glycolate.
- Claim 18 (glidant): silicon dioxide or talc.
- Claim 19 (humectant): glyceryl monostearate or magnesium stearate.
Finally, claims 20-24 recite specific excipient combinations:
- Claim 20: croscarmose sodium + mannitol
- Claim 21: magnesium stearate + talc
- Claim 22: croscarmose sodium + mannitol + magnesium stearate
- Claim 23: croscarmose sodium + mannitol + talc
- Claim 24: croscarmose sodium + mannitol + magnesium stearate + talc
Legal scope impact
- These dependent claims operate like a “matrix”: if the accused formulation uses those exact excipient selections, it likely lands within those narrower claims.
- The excipient language is not fully open-ended: for each dependent step, it restricts to selected member(s) from enumerated groups. That gives clear formulation levers for a generic.
Claim-by-claim “breadth map”: where infringement risk concentrates
Infringement likely if all of the following align
- Combination present: product includes both Formula I and Formula II.
- Ratio in range: product ratio falls within 1:200 to 1:2000 (Claim 2) and possibly a tighter window (Claims 3-6).
- Oral solid format: product is a tablet or capsule (Claim 7).
- Optional narrowing triggers: Formula II is tosylate (Claim 8) and/or excipient sets match (Claims 10-24).
Practical exposure ranking (from broadest to narrowest)
- Claim 1: Formula I + Formula II (salt/free base either way)
- Claim 2: ratio 1:200 to 1:2000
- Claim 7: tablet/capsule
- Claim 9-11: excipient “at least one carrier” within permitted functional classes
- Claims 12-19: specific excipient examples within those classes
- Claims 20-24: specific multi-excipient combinations
- Claim 8: Formula II specifically tosylate
How does the weight-ratio limitation affect generic entry risk for this patent?
Short answer: The ratio bands (1:200 to 1:2000; then narrower) are one of the cleanest potential design-around variables because they are numeric.
Ratio bands in the claim set
| Claim |
Formula I : Formula II weight ratio |
| 2 |
1:200 to 1:2000 |
| 3 |
1:245 to 1:1000 |
| 4 |
1:250 to 1:550 |
| 5 |
1:300 to 1:500 |
| 6 |
1:285 to 1:460 |
Design-around logic
- If a competitor intentionally formulates outside 1:200 to 1:2000, it aims to avoid Claim 2 and all ratio-dependent claims (3-6).
- If it stays within the broad band, then it will still potentially infringe depending on the exact ratio and whether it also meets tablet/capsule and excipient selections.
Litigation framing likely to be used
- Numerics favor comparison-by-measurement (composition testing, batch specs, and analytical method validation).
- Expect disputes over:
- which analytical method determines the weight ratio (free base vs salt forms can shift measured weight),
- whether “weight ratio” is based on active ingredient equivalents or as-manufactured salt mass.
What does the excipient language cover: how narrowly are formulation claims written?
Short answer: Excipient coverage is dependent and enumerated, with both functional class and specific named excipient members, culminating in several fixed excipient combinations.
Excipient structure in the claims
- Claim 10 defines broad excipient categories (anti-oxidant, binder, diluent, disintegrant, etc.).
- Claim 11 restricts the allowed categories to a subset: antioxidant, binder, diluent, disintegrant, filler, glidant, lubricant, sweetener, thickening agent.
- Claims 12-19 define specific exemplars within categories.
- Claims 20-24 recite specific combinations of selected excipients.
What this means for formulation strategy
- A product using a different binder or diluent not listed in the dependent claim chain may avoid the narrow excipient claims but still risk the broader composition claims if the actives and ratio remain within the Claim 1/2 framework.
What patents protect the same two-compound combination in the US, and how do these claims typically map to an estate?
Short answer: A meaningful US landscape analysis requires the identity of the actual Formula I and Formula II structures or at least the patent’s publication/application family and related Orange Book listings. Without those identifiers, it is not possible to reliably enumerate other US patents, continuations, divisionals, or related composition/method patents in a way that would be accurate for clearance, licensing, or litigation.
What is the Orange Book status of US Patent 12,410,195 and which FDA products are exposed?
Short answer: Orange Book status depends on the associated NDA/ANDA/BLA and listed patents. With only the claim text and the patent number, the Orange Book linkage cannot be determined with sufficient precision to produce a correct product-and-listed-patent table.
What generic entry risks exist for products that combine Formula I and Formula II?
Short answer: Entry risk depends on whether competitors match each claim axis: (i) both actives, (ii) the ratio bands, (iii) tablet/capsule format, and (iv) the specific excipient sets and optional tosylate salt selection.
Risk scenarios
- High risk: competitor submits a product with both actives, ratio within 1:200 to 1:2000, oral solid format, and uses excipients falling within the dependent claim chain.
- Medium risk: competitor avoids the narrow excipient claims by using different excipients but remains within Claim 1 and Claim 2.
- Lower risk: competitor changes the active ratio to move outside 1:200 to 1:2000 or avoids the tablet/capsule limitation, depending on how the overall claim construction is applied at infringement time.
How long does this patent protect the composition: expiration timing for US 12,410,195?
Short answer: Expiration timing requires the application filing date, USPTO patent term adjustment, any terminal disclaimer, and whether it is a continuation or has multiple priority dates. Those data are not available in the prompt.
Key takeaways
- US 12,410,195 protects a combination composition that contains Formula I + Formula II as free base or pharmaceutically acceptable salts (Claim 1).
- The most formulation-sensitive restriction is active weight ratio: 1:200 to 1:2000, with tighter sub-ranges down to 1:285 to 1:460 (Claims 2-6).
- Tablet or capsule is a meaningful dependent narrowing (Claim 7), and Formula II tosylate is a further narrowing (Claim 8).
- Excipient coverage is dependent and enumerated, progressing from broad excipient classes to named examples and ending with several fixed excipient combination claims (Claims 10-24).
- Competitive exposure will be driven by whether an accused product matches the required two-actives combination and the ratio first, then by salt form and tablet excipient composition second.
FAQs
1) Does US 12,410,195 require a specific salt for Formula I or is free base allowed?
Claim 1 allows Formula I in free base or pharmaceutically acceptable salt.
2) What ratio would avoid all ratio-dependent claims (Claims 3-6) under this patent?
It would need to fall outside the parent ratio window in Claim 2 (1:200 to 1:2000).
3) If Formula II is not the toluene sulfonic acid (tosylate) salt, is the product still covered?
Coverage under Claim 8 would be avoided, but Claim 1 may still be implicated if Formula II is present in free base or another pharmaceutically acceptable salt.
4) Do excipient claims require a complete match to the exact listed combination in Claims 20-24?
To satisfy those specific dependent claims, yes, the cited excipient set must match the claim’s required selections.
5) Can a capsule with different excipients still infringe this patent?
Yes, if it meets the independent combination requirements (and the ratio limitation where applicable), excipient changes may avoid only the narrower dependent excipient-specific claims.
References
No sources cited.
More… ↓
⤷ Start Trial
|
